, Masalha, Muhamed1,3
, Domachevsky, Liran2
, Bernstine, Hanna2
, Groshar, David2
, Gindi, Nichal2
, Lockman, Yehudit2
Department of Otolaryngology, Head and Neck Surgery, Assuta Medical Center,Tel Aviv. Affiliated with Ben Gurion University- Faculty of Medicine, Beer Seva, Israel
2 Department of Radiology, Assuta Medical Center,Tel Aviv. Affiliated with Ben Gurion University- Faculty of Medicine, Beer Seva, Israel
Department of Otolaryngology, Head and Neck Surgery, Emeq Medical Center. Affiliated with Technion University, Haifa, Israel
Although preoperative localization of parathyroid adenoma is usually obtained by the combination of ultrasound and scintigraphy with [99mTc] methoxyisobutylisonitrile ([99mTc] MIBI), a role still exists for other localizing studies. We evaluated the role of F18- Fluorcholine (FCH) Neck PET/MR as a novel tool for localizing parathyroid adenoma.
22 patients with primary hyperparathyroidism (18 women and four men, mean age 60±10 years) were prospectively recruited. A F18- Fluorcholine (FCH) dedicated neck PET/MR were performed. Standardized Uptake Values (SUV) and Metabolic Tumor Volume (MTV) in the parathyroid were detected and compared with uptake values of thyroid gland and the sternocleidomastoid muscle.
Increased uptake of FCH in parathyroid adenomas was shown in 20 out of 22 patients (91%). The SUV measured for parathyroid adenoma was significantly higher in the parathyroid adenoma compared with the thyroid gland and the sternocleidomastoid muscle. In two patients; one with a large hematoma after biopsy and a second with a very large multinodular goiter, the precise localization was compromised.
Discussion & Conclusion:
F18- Fluorocholine (FCH) PET/MR is a promising emerging modality for localizing parathyroid adenoma.